Weekly Funding Opportunities

[Med Research]

March of Dimes: Child and Mental Health Research<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.marchofdimes.org_research_request-2Dfor-2Dapplications-2D2020-2Dresearch-2Dprogram.aspx&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=Q6lML6iGIl_S6FgwjkiFAlvF0mVqQF9edKbAAZPRZEw&e=>
The March of Dimes is accepting applications through its 2019 Research Program for research on pregnancy-related disorders; the prevention and treatment of diseases in either mom, dad, or baby that lead to premature birth; genetic and environmentally-induced birth defects; opioid exposure and dependency; and health disparities within all these areas.
Applicants are invited to submit LOIs in one of the following categories:

  *   Innovative Challenge Grants -- Six-month grants of $50,000 will be awarded to proposals with clear-cut deliverables defined within the application. If the deliverables are achieved, there's a possibility of a second award in the amount of $100,000 to $500,000 over twelve months.
  *   Novel Discovery Grants -- Proposals anywhere on the translational spectrum will be considered, including translation to humans, translation to patients, translation to practice, and translation to population health. Grants of $50,000 to $100,000 will be awarded for the first twelve months, with the option of an additional twelve months of support if significant progress is made.
  *   Clinical and Social Science Challenge Grants -- MoD seeks research that explores health equity in order to reduce disparities; opioid dependency in mom, dad, and baby to mitigate the rise in Neonatal Abstinence Syndrome; and premature birth and maternal/infant mortality. Sic-month grants of $50,000 to $100,000 will be awarded to proposals with clear-cut deliverables defined within the application. If the deliverables are achieved, there's a possibility of a second award in the amount of $100,000 to $500,000 over twelve months.
Letters of intent are due April 19, 2019. Med-RA deadline to receive draft documents: April 5.

Prostate Cancer Foundation: Challenge Awards<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.pcf.org_wp-2Dcontent_uploads_2019_01_2019-5FChallenge-5FAwards-5FRFA.pdf&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=HueqndbYmbRUShvp9hPKruYdRrGSXgtoXx7pHsFoMSE&e=>
Through the program, awards of up to $1 million over two years will be made to teams of at least three investigators conducting large-scale research projects focused on metastatic, lethal prostate cancer. Teams must be based at a nonprofit academic research center, include one young investigator (as defined by the foundation), and be comprised of investigators at either a single institution or at several institutions. The foundation seeks research proposals dedicated to the following priority areas: immunotherapy for the treatment of metastatic, lethal prostate cancer; targeted radionuclide therapy for advanced prostate cancer; new systemic precision treatments for metastatic, lethal prostate cancer (including those targeting the currently "undruggable"); first-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer; mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system, chemotherapy, and other targeted agents; correlative research around either clinical trials of novel agents or strategies or standard of care; the development or validation of biomarkers that can guide therapy in patients or further understanding of the mechanisms by which therapies work; tumor microenvironment signaling related to cancer progression (including the immune component); and new data science technologies for analysis of genomic information to advance precision medicine.
Currently unfunded high-risk projects are encouraged. Young investigator team members may hold the title of postdoctoral fellow, instructor, research associate, or assistant professor (or equivalent), and should be within six years of the completion of a professional degree (MD, DO, PhD, MD-PhD, DSc, ScD, DDM, DDS, DMD, MBBS, or equivalent) or subsequent mentored academic or clinical training program. In addition, s/he must not receive more than $200,000 in direct research funding from all sources (including institutional funds) during the two-year term of the award.
Due April 22, 2019. Med-RA deadline to receive draft documents: April 8.

Michael J. Fox Foundation: Biology of Astrocytes in Parkinson's<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.michaeljfox.org_research_grant-2Ddetail.php-3Fid-3D42&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=jb3mh4X6jtKprAwKgLIoJwvz0Fev0qrh1UgDqpYfOe4&e=>
The Michael J. Fox Foundation will award one-year to 18-month grants for studies that explore the role of astrocytes in Parkinson's disease (PD) pathology and the potential for astrocyte-focused therapeutics. The goals of this funding program are to further understanding of astrocyte biology in Parkinson's and to rationalize the pursuit of astrocyte-specific targets and/or pathways for the treatment of the disease.
Preference will be given to applications that focus on or include the following:

  *   Role of astrocytes in initiating and/or propagating Parkinson's disease pathology, including alpha-synuclein spread, dopaminergic neuron death, inflammation and senescence
  *   Consequences of dysfunction and/or mutations of common PD targets, including alpha-synuclein, LRRK2, GBA, PRKN and PINK1
  *   Manipulation of astrocyte activity and/or astrocyte-specific pathways to assess the potential of targeted astrocyte therapies on disease biology and/or symptoms
  *   Parkinson's disease models with high construct validity to human PD, including patient-derived material (such as iPSCs or cerebral organoids) and/or well characterized animal models and primary cells; Examination of human brain samples to answer specific hypotheses is also acceptable
  *   Targets, pathways and mechanisms proposed for investigation should have reasonable links to PD.
Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5.

Michael J. Fox Foundation: Assay Development and Validation for Quantifying Oligomeric Alpha-Synuclein<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.michaeljfox.org_research_grant-2Ddetail.php-3Fid-3D43&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=VOv0XKabMvG8TAMJ_hMnXK8ynQM9iGpY3pSCierC0QQ&e=>
The Michael J. Fox Foundation will award one-year grants for research to advance the development, optimization and validation of assays to quantify oligomeric alpha-synuclein in human body fluids. These biofluids may include blood, cerebrospinal fluid, saliva and tears. Prior research suggests that alpha-synuclein quantification in accessible body fluids may serve as a biomarker of disease diagnosis, target engagement, pharmacodynamic response and/or patient stratification.

  *   Immuno-assays should have a renewable source of the antibodies used. Optimization and/or adaptation of existent assays to different biological matrices will also be considered.
  *   Projects should propose to develop or optimize assays with superior performance in quantifying oligomeric alpha-synuclein and, at the end of the grant, should be able to present several performance parameters for further validation such as robustness, precision, trueness, uncertainty, limits of detection and quantification, dilutional linearity, parallelism, recovery, selectivity, and sample stability.
Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5.

Michael J. Fox Foundation: Imaging Biomarkers to Track Disease Progression and Therapeutic Efficacy<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.michaeljfox.org_research_grant-2Ddetail.php-3Fid-3D41&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=ho8SoovhK84NYqaFLCQF_plgCCar1cu8b5Js2cvBC0U&e=>
The Michael J. Fox Foundation will award one- to three-year grants to develop imaging markers for use in disease-modifying clinical trials. Imaging is a powerful tool that can be used to visualize the structure and function of the brain in living subjects. While a variety of imaging techniques are available, including positron emission tomography (PET), single photon emission computed tomography (SPECT) and magnetic resonance imaging (MRI), none have been demonstrated to be a sensitive, specific and reliable biomarker test for the presence and progression of PD.
Applications must focus on developing robust and precise imaging markers.

  *   Priority targets for this program are alpha-synuclein and neuroinflammation, but applications may focus on other promising therapeutic targets.
  *   Imaging modalities can include PET, SPECT and MRI.
  *   Projects should aim to develop novel imaging biomarkers as opposed to prospectively collecting data using existing technologies. Prospective data collection is appropriate only if a novel imaging technique or tracer is being tested. Novel data analysis techniques may be proposed but should utilize existing data sets.
  *   Examples of projects that are appropriate for this program include development of novel PET or SPECT tracers, early validation of new tracers, and development and validation of novel MRI techniques.
Pre-proposals due April 19, 2019. Med-RA deadline to receive draft documents: April 5.

Robert Wood Johnson Foundation: Pioneering Ideas Brief Proposal-Culture of Health<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.rwjf.org_en_how-2Dwe-2Dwork_submit-2Da-2Dproposal.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=0Wj5i62aD35wBzduNgZl-NM1cSa00nTZeXjP637jfys&e=>
The goal of the Pioneering Ideas Brief Proposal funding opportunity is to explore; to look into the future and put health first as we design for changes in how we live, learn, work and play; to wade into uncharted territory in order to better understand what new trends, opportunities and breakthrough ideas can enable everyone in America to live the healthiest life possible.
While improving the status quo is vital to the health and well-being of millions of Americans now, the Pioneering Ideas Brief Proposal opportunity reaches beyond incremental changes to explore the ideas and trends that will influence the trajectory and future of health. Ultimately, we support work that will help us learn what a Culture of Health<https://urldefense.proofpoint.com/v2/url?u=https-3A__www.rwjf.org_en_cultureofhealth_about.html&d=DwIFAg&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=fqiHjDGxQyidzf0BYRUMRGXkjkanDnAVgPBeuU4t8A0&s=Z3FLOPDlEkJoApmQ9WYueso9T5MVxDkGexOZ9x3BXiY&e=> can look like-and how we can get there.
Brief proposals are reviewed on a rolling basis, but the final deadline for submitting is October 15, 2019. Med-RA deadline to receive draft documents: Ten business days before submission.

To search for additional funding opportunities, please visit CoM's unofficial funding opportunities blog<https://urldefense.proofpoint.com/v2/url?u=https-3A__fsucomgrants.wordpress.com_&d=DwMGaQ&c=HPMtquzZjKY31rtkyGRFnQ&r=EXkFPz4CfHp2YvDR6s1e2OHGNt7ixTIGEDylKw2SIo1FQ8O9soOgOzmn5ZTHU62o&m=-WQkPIXZLCgXlX-d14DY8B-SG-GvP9FZHr_Gv8sUuTQ&s=ErAzzubGxiJsWCKGnlFjfXV6980C-DCl-AxzFLHMVYQ&e=>.







-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.fsu.edu/pipermail/com_funding_opportunities/attachments/20190404/9326b17e/attachment.html>